The themes Agilent Technologies is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Los porcentajes de ingresos son estimaciones para nine months ended July 31, 2026, no cifras de un informe oficial.
Infinity III liquid chromatography systems
Instruments that separate the substances in a liquid sample so a laboratory can identify and measure them.
8890B and 8860B gas chromatographs
Instruments that separate and measure substances that can be turned into gas, including chemicals in fuels and contaminants in food.
9500 triple-quadrupole inductively coupled plasma mass spectrometer
An instrument that measures very small amounts of metals and other elements, including in samples used in semiconductor manufacturing.
Altura liquid chromatography columns
Replaceable tubes that separate substances inside a chromatography system, including in testing of protein-based and nucleic-acid medicines.
Dako Omnis pathology systems
Automated instruments and related supplies used by clinical laboratories to stain and examine tissue samples for cancer diagnosis.
Oligonucleotide contract manufacturing
Manufacturing of short DNA- or RNA-like drug ingredients for pharmaceutical customers, from development through commercial production.
Estados financieros completos →
Agilent makes instruments that help laboratories identify and measure the chemicals, cells and other materials in samples. It also sells the supplies used with those instruments, maintains lab equipment, and provides software for collecting and managing test results. For drug companies, Agilent also makes ingredients used in some medicines and manufactures certain drug materials under contract.
Construido a partir de los propios informes de Agilent Technologies, Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
A · NYSE · Healthcare · Diagnostics and Research
176,91 US$-0,5 %cierre 11 nov
Próximos resultados: 23 de noviembre de 2026 · tras el cierre
Cifras hasta el 31 de julio de 2026, del 10-Q presentado el 1 de septiembre de 2026
Agilent sells laboratory supplies and maintenance services, plus scientific instruments, to pharmaceutical companies, hospitals, research labs and testing laboratories.
Previsión de la empresa: ingresos de de 7,5B US$ a 7,5B US$ para Año fiscal 2026 — un 7,9 % más que un año antes
Grade B+
La franja bajo el precio muestra la calificación en cada fecha, calculada solo con los informes ya públicos en ese momento.
Mostrando 2 de 40 trimestres del historial de calificaciones de Agilent Technologies, Inc.. Los otros 38 llegan hasta diciembre de 2016.